10-Q 1 pfe-20221002.htm 10-Q pfe-20221002
000007800312/312022Q3falseP3MP1YP1Y00000780032022-01-012022-10-020000078003us-gaap:CommonStockMember2022-01-012022-10-020000078003pfe:NotesDue20271.000Member2022-01-012022-10-0200000780032022-11-04xbrli:shares00000780032022-07-042022-10-02iso4217:USD00000780032021-07-052021-10-0300000780032021-01-012021-10-03iso4217:USDxbrli:shares00000780032022-10-0200000780032021-12-310000078003us-gaap:CommonStockMember2022-07-030000078003us-gaap:AdditionalPaidInCapitalMember2022-07-030000078003us-gaap:TreasuryStockMember2022-07-030000078003us-gaap:RetainedEarningsMember2022-07-030000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-030000078003us-gaap:ParentMember2022-07-030000078003us-gaap:NoncontrollingInterestMember2022-07-0300000780032022-07-030000078003us-gaap:RetainedEarningsMember2022-07-042022-10-020000078003us-gaap:ParentMember2022-07-042022-10-020000078003us-gaap:NoncontrollingInterestMember2022-07-042022-10-020000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-042022-10-020000078003us-gaap:CommonStockMember2022-07-042022-10-020000078003us-gaap:AdditionalPaidInCapitalMember2022-07-042022-10-020000078003us-gaap:TreasuryStockMember2022-07-042022-10-020000078003us-gaap:CommonStockMember2022-10-020000078003us-gaap:AdditionalPaidInCapitalMember2022-10-020000078003us-gaap:TreasuryStockMember2022-10-020000078003us-gaap:RetainedEarningsMember2022-10-020000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-10-020000078003us-gaap:ParentMember2022-10-020000078003us-gaap:NoncontrollingInterestMember2022-10-020000078003us-gaap:CommonStockMember2021-07-040000078003us-gaap:AdditionalPaidInCapitalMember2021-07-040000078003us-gaap:TreasuryStockMember2021-07-040000078003us-gaap:RetainedEarningsMember2021-07-040000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-040000078003us-gaap:ParentMember2021-07-040000078003us-gaap:NoncontrollingInterestMember2021-07-0400000780032021-07-040000078003us-gaap:RetainedEarningsMember2021-07-052021-10-030000078003us-gaap:ParentMember2021-07-052021-10-030000078003us-gaap:NoncontrollingInterestMember2021-07-052021-10-030000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-052021-10-030000078003us-gaap:CommonStockMember2021-07-052021-10-030000078003us-gaap:AdditionalPaidInCapitalMember2021-07-052021-10-030000078003us-gaap:TreasuryStockMember2021-07-052021-10-030000078003us-gaap:CommonStockMember2021-10-030000078003us-gaap:AdditionalPaidInCapitalMember2021-10-030000078003us-gaap:TreasuryStockMember2021-10-030000078003us-gaap:RetainedEarningsMember2021-10-030000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-10-030000078003us-gaap:ParentMember2021-10-030000078003us-gaap:NoncontrollingInterestMember2021-10-0300000780032021-10-030000078003us-gaap:CommonStockMember2021-12-310000078003us-gaap:AdditionalPaidInCapitalMember2021-12-310000078003us-gaap:TreasuryStockMember2021-12-310000078003us-gaap:RetainedEarningsMember2021-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000078003us-gaap:ParentMember2021-12-310000078003us-gaap:NoncontrollingInterestMember2021-12-310000078003us-gaap:RetainedEarningsMember2022-01-012022-10-020000078003us-gaap:ParentMember2022-01-012022-10-020000078003us-gaap:NoncontrollingInterestMember2022-01-012022-10-020000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-10-020000078003us-gaap:CommonStockMember2022-01-012022-10-020000078003us-gaap:AdditionalPaidInCapitalMember2022-01-012022-10-020000078003us-gaap:TreasuryStockMember2022-01-012022-10-020000078003us-gaap:CommonStockMember2020-12-310000078003us-gaap:AdditionalPaidInCapitalMember2020-12-310000078003us-gaap:TreasuryStockMember2020-12-310000078003us-gaap:RetainedEarningsMember2020-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000078003us-gaap:ParentMember2020-12-310000078003us-gaap:NoncontrollingInterestMember2020-12-3100000780032020-12-310000078003us-gaap:RetainedEarningsMember2021-01-012021-10-030000078003us-gaap:ParentMember2021-01-012021-10-030000078003us-gaap:NoncontrollingInterestMember2021-01-012021-10-030000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-10-030000078003us-gaap:CommonStockMember2021-01-012021-10-030000078003us-gaap:AdditionalPaidInCapitalMember2021-01-012021-10-030000078003us-gaap:TreasuryStockMember2021-01-012021-10-03pfe:operatingSegment0000078003us-gaap:AccountsReceivableMember2022-10-020000078003us-gaap:AccountsReceivableMember2021-12-310000078003us-gaap:OtherCurrentLiabilitiesMember2022-10-020000078003us-gaap:OtherCurrentLiabilitiesMember2021-12-310000078003us-gaap:OtherNoncurrentLiabilitiesMember2022-10-020000078003us-gaap:OtherNoncurrentLiabilitiesMember2021-12-310000078003pfe:ReViralAssetAcquisitionMember2022-06-092022-06-090000078003pfe:ArenaMember2022-03-110000078003pfe:ArenaMember2022-03-112022-03-110000078003pfe:ArenaMemberpfe:RestructuringChargesAndAcquisitionRelatedCostsMember2022-03-112022-03-110000078003pfe:ArenaMemberus-gaap:InProcessResearchAndDevelopmentMember2022-03-110000078003pfe:ArenaMemberus-gaap:LicensingAgreementsMember2022-03-110000078003pfe:ViatrisMember2022-10-020000078003pfe:ViatrisMember2021-12-310000078003pfe:ViatrisMember2021-01-012021-04-040000078003pfe:EpiPenMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMemberpfe:MeridianMember2021-01-012021-10-030000078003pfe:ConsumerHealthcareJVHaleonMember2019-07-31xbrli:pure0000078003pfe:ConsumerHealthcareJVHaleonMemberpfe:GSKMember2019-07-310000078003pfe:ConsumerHealthcareJVHaleonMember2022-07-180000078003pfe:ConsumerHealthcareJVHaleonMember2022-10-020000078003pfe:ConsumerHealthcareJVHaleonMember2021-12-310000078003pfe:ConsumerHealthcareJVHaleonMember2022-01-012022-10-020000078003pfe:ConsumerHealthcareJVHaleonMember2022-07-042022-10-020000078003pfe:ConsumerHealthcareJVHaleonMember2021-07-052021-10-030000078003pfe:ConsumerHealthcareJVHaleonMember2021-01-012021-10-030000078003pfe:ConsumerHealthcareJVHaleonMember2022-04-012022-06-300000078003pfe:ConsumerHealthcareJVHaleonMember2021-04-012021-06-300000078003pfe:ConsumerHealthcareJVHaleonMember2021-10-012022-06-300000078003pfe:ConsumerHealthcareJVHaleonMember2020-10-012021-06-300000078003us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberpfe:ConsumerHealthcareJVHaleonMemberpfe:GSKMember2022-03-310000078003pfe:ConsumerHealthcareJVSeniorNotesUSDDenominatedMemberpfe:ConsumerHealthcareJVHaleonMemberus-gaap:SeniorNotesMember2022-03-310000078003pfe:ConsumerHealthcareJVHaleonMemberus-gaap:SeniorNotesMemberpfe:ConsumerHealthcareJVSeniorNotesEURDenominatedMember2022-03-31iso4217:EUR0000078003pfe:ConsumerHealthcareJVSeniorNotesGBPDenominatedMemberpfe:ConsumerHealthcareJVHaleonMemberus-gaap:SeniorNotesMember2022-03-31iso4217:GBP0000078003pfe:ConsumerHealthcareJVHaleonMember2022-03-310000078003us-gaap:LoansPayableMemberpfe:A1365ConsumerHealthcareJVLoanMember2022-07-030000078003pfe:ConsumerHealthcareJVHaleonMember2022-07-012022-07-310000078003us-gaap:LoansPayableMemberpfe:A1365ConsumerHealthcareJVLoanMember2022-07-310000078003us-gaap:CollaborativeArrangementMemberpfe:BiohavenMember2022-01-042022-01-040000078003us-gaap:CollaborativeArrangementMemberpfe:BiohavenMember2022-01-040000078003us-gaap:CollaborativeArrangementMemberpfe:BiohavenMemberpfe:ResearchAndDevelopmentInProcessMember2022-01-042022-01-040000078003pfe:BiohavenMemberus-gaap:SubsequentEventMember2022-10-310000078003pfe:BiohavenMemberus-gaap:SubsequentEventMember2022-10-012022-10-310000078003pfe:CorporateEnablingFunctionsMemberpfe:FocusedCompanyPlanMember2022-10-020000078003pfe:GoToMarketModelMemberpfe:FocusedCompanyPlanMember2022-10-020000078003pfe:ManufacturingOptimizationMemberpfe:FocusedCompanyPlanMember2022-10-020000078003pfe:ManufacturingOptimizationMemberpfe:FocusedCompanyPlanMember2022-01-012022-10-020000078003pfe:FocusedCompanyPlanMember2022-10-020000078003pfe:BiopharmaSegmentMemberpfe:FocusedCompanyPlanMember2022-10-020000078003us-gaap:OtherNonoperatingIncomeExpenseMember2022-07-042022-10-020000078003us-gaap:OtherNonoperatingIncomeExpenseMember2021-07-052021-10-030000078003us-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-10-020000078003us-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-10-030000078003us-gaap:CostOfSalesMember2022-07-042022-10-020000078003us-gaap:CostOfSalesMember2021-07-052021-10-030000078003us-gaap:CostOfSalesMember2022-01-012022-10-020000078003us-gaap:CostOfSalesMember2021-01-012021-10-030000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-042022-10-020000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-052021-10-030000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-10-020000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-10-030000078003us-gaap:ResearchAndDevelopmentExpenseMember2022-07-042022-10-020000078003us-gaap:ResearchAndDevelopmentExpenseMember2021-07-052021-10-030000078003us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-10-020000078003us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMember2021-01-012021-10-030000078003pfe:ArenaMemberpfe:RestructuringChargesAndAcquisitionRelatedCostsMember2022-01-012022-04-030000078003us-gaap:EmployeeSeveranceMember2021-12-310000078003pfe:AssetImpairmentsMember2021-12-310000078003us-gaap:OtherRestructuringMember2021-12-310000078003us-gaap:EmployeeSeveranceMember2022-01-012022-10-020000078003pfe:AssetImpairmentsMember2022-01-012022-10-020000078003us-gaap:OtherRestructuringMember2022-01-012022-10-020000078003us-gaap:EmployeeSeveranceMember2022-10-020000078003pfe:AssetImpairmentsMember2022-10-020000078003us-gaap:OtherRestructuringMember2022-10-020000078003pfe:BioNTechCerevelTherapeuticsLLCAndArvinasMember2022-01-012022-10-020000078003pfe:BioNTechAndCerevelTherapeuticsLLCMember2021-07-052021-10-030000078003pfe:BioNTechAndCerevelTherapeuticsLLCMember2021-01-012021-10-030000078003us-gaap:CollaborativeArrangementMemberpfe:BioNTechMember2021-01-012021-10-030000078003us-gaap:InProcessResearchAndDevelopmentMember2022-10-020000078003us-gaap:FairValueInputsLevel1Memberus-gaap:InProcessResearchAndDevelopmentMember2022-10-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:InProcessResearchAndDevelopmentMember2022-10-020000078003us-gaap:FairValueInputsLevel3Memberus-gaap:InProcessResearchAndDevelopmentMember2022-10-020000078003us-gaap:InProcessResearchAndDevelopmentMember2022-01-012022-10-020000078003us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2021-12-310000078003us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-10-020000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-10-020000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-10-020000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2022-01-012022-10-020000078003us-gaap:AccumulatedTranslationAdjustmentMember2022-10-020000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-10-020000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-10-020000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2022-10-020000078003us-gaap:MoneyMarketFundsMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:MoneyMarketFundsMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:MoneyMarketFundsMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:MoneyMarketFundsMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003pfe:LongtermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003pfe:LongtermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003pfe:LongtermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:CorporateDebtSecuritiesMemberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:CorporateDebtSecuritiesMemberpfe:LongtermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-10-020000078003us-gaap:CorporateDebtSecuritiesMemberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:CorporateDebtSecuritiesMemberpfe:LongtermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberpfe:LongtermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000078003us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-10-020000078003us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-10-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310000078003us-gaap:ForeignGovernmentDebtSecuritiesMember2022-10-020000078003us-gaap:ForeignGovernmentDebtSecuritiesMember2021-12-310000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-10-020000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310000078003us-gaap:CorporateDebtSecuritiesMember2022-10-020000078003us-gaap:CorporateDebtSecuritiesMember2021-12-310000078003us-gaap:BankTimeDepositsMember2022-10-020000078003us-gaap:BankTimeDepositsMember2021-12-310000078003us-gaap:UnsecuredDebtMember2022-10-020000078003us-gaap:UnsecuredDebtMember2021-12-310000078003us-gaap:ForeignExchangeContractMember2022-01-012022-10-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-10-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-12-310000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2022-10-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2021-12-310000078003us-gaap:DesignatedAsHedgingInstrumentMember2022-10-020000078003us-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-10-020000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-12-310000078003us-gaap:SalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-10-020000078003us-gaap:SalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-12-310000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-07-042022-10-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-07-052021-10-030000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:InterestRateContractMember2022-07-042022-10-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:InterestRateContractMember2021-07-052021-10-030000078003us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-07-042022-10-020000078003us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-07-052021-10-030000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyShortTermBorrowingsMember2022-07-042022-10-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyShortTermBorrowingsMember2021-07-052021-10-030000078003pfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-07-042022-10-020000078003pfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-07-042022-10-020000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-07-052021-10-030000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-01-012022-10-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-012021-10-030000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:InterestRateContractMember2022-01-012022-10-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:InterestRateContractMember2021-01-012021-10-030000078003us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-01-012022-10-020000078003us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-01-012021-10-030000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyShortTermBorrowingsMember2022-01-012022-10-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyShortTermBorrowingsMember2021-01-012021-10-030000078003pfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-10-020000078003pfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-01-012022-10-020000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-01-012021-10-030000078003us-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-07-042022-10-020000078003us-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-01-012022-10-020000078003us-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-07-052021-10-030000078003us-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-01-012021-10-030000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-01-012022-10-020000078003pfe:ForeignCurrencyShortTermBorrowingsMember2021-12-310000078003pfe:ForeignCurrencyDebtMember2022-10-020000078003pfe:ForeignCurrencyDebtMember2021-12-310000078003us-gaap:ShortTermDebtMember2022-10-020000078003us-gaap:ShortTermDebtMember2021-12-310000078003us-gaap:LongTermDebtMember2022-10-020000078003us-gaap:LongTermDebtMember2021-12-310000078003us-gaap:CollaborativeArrangementMemberpfe:ComirnatyMemberpfe:BioNTechMember2022-10-020000078003us-gaap:CollaborativeArrangementMemberpfe:ComirnatyMemberpfe:BioNTechMember2021-12-310000078003us-gaap:DevelopedTechnologyRightsMember2022-10-020000078003us-gaap:DevelopedTechnologyRightsMember2021-12-310000078003us-gaap:TradeNamesMember2022-10-020000078003us-gaap:TradeNamesMember2021-12-310000078003pfe:LicensingAgreementsAndOtherMember2022-10-020000078003pfe:LicensingAgreementsAndOtherMember2021-12-310000078003us-gaap:TradeNamesMember2022-10-020000078003us-gaap:TradeNamesMember2021-12-310000078003us-gaap:InProcessResearchAndDevelopmentMember2021-12-310000078003pfe:LicensingAgreementsAndOtherMember2022-10-020000078003pfe:LicensingAgreementsAndOtherMember2021-12-310000078003country:USus-gaap:PensionPlansDefinedBenefitMember2022-07-042022-10-020000078003country:USus-gaap:PensionPlansDefinedBenefitMember2021-07-052021-10-030000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-07-042022-10-020000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-07-052021-10-030000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-042022-10-020000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-052021-10-030000078003country:USus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-10-020000078003country:USus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-10-030000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-10-020000078003us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-10-030000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-10-020000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-10-030000078003us-gaap:PendingLitigationMemberpfe:PfizerAndVersusSeveralGenericManufacturersMemberpfe:PatentInfringementMemberpfe:Expiring2030Memberpfe:MektoviMember2022-08-012022-08-31pfe:patent0000078003us-gaap:PendingLitigationMemberpfe:PfizerAndVersusSeveralGenericManufacturersMemberpfe:PatentInfringementMemberpfe:Expiring2033Memberpfe:MektoviMember2022-08-012022-08-310000078003us-gaap:PendingLitigationMemberpfe:PfizerAndVersusSeveralGenericManufacturersMemberpfe:PatentInfringementMemberpfe:MektoviMember2022-08-012022-08-310000078003pfe:ModernaTXPatentInfringementCaseMemberpfe:ComirnatyMember2022-09-012022-09-300000078003us-gaap:PendingLitigationMemberpfe:EliquisMemberpfe:PfizerandBMSVersusSeveralGenericManufacturersMemberpfe:PatentInfringementMember2017-01-012017-12-31pfe:defendant0000078003pfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMemberpfe:ComirnatyMember2022-07-012022-07-310000078003us-gaap:PendingLitigationMemberpfe:DocetaxelMemberpfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember2018-01-012018-12-31pfe:manufacturer0000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2022-07-042022-10-020000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2021-07-052021-10-030000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2022-01-012022-10-020000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2021-01-012021-10-030000078003us-gaap:CorporateNonSegmentMember2022-07-042022-10-020000078003us-gaap:CorporateNonSegmentMember2021-07-052021-10-030000078003us-gaap:CorporateNonSegmentMember2022-01-012022-10-020000078003us-gaap:CorporateNonSegmentMember2021-01-012021-10-030000078003pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMemberus-gaap:MaterialReconcilingItemsMember2022-07-042022-10-020000078003pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMemberus-gaap:MaterialReconcilingItemsMember2021-07-052021-10-030000078003pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMemberus-gaap:MaterialReconcilingItemsMember2022-01-012022-10-020000078003pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMemberus-gaap:MaterialReconcilingItemsMember2021-01-012021-10-030000078003pfe:ReconcilingItemsAcquisitionRelatedCostsMemberus-gaap:MaterialReconcilingItemsMember2022-07-042022-10-020000078003pfe:ReconcilingItemsAcquisitionRelatedCostsMemberus-gaap:MaterialReconcilingItemsMember2021-07-052021-10-030000078003pfe:ReconcilingItemsAcquisitionRelatedCostsMemberus-gaap:MaterialReconcilingItemsMember2022-01-012022-10-020000078003pfe:ReconcilingItemsAcquisitionRelatedCostsMemberus-gaap:MaterialReconcilingItemsMember2021-01-012021-10-030000078003pfe:ReconcilingItemsOtherMemberus-gaap:MaterialReconcilingItemsMember2022-07-042022-10-020000078003pfe:ReconcilingItemsOtherMemberus-gaap:MaterialReconcilingItemsMember2021-07-052021-10-030000078003pfe:ReconcilingItemsOtherMemberus-gaap:MaterialReconcilingItemsMember2022-01-012022-10-020000078003pfe:ReconcilingItemsOtherMemberus-gaap:MaterialReconcilingItemsMember2021-01-012021-10-030000078003pfe:ViivHealthcareLimitedMember2022-07-042022-10-020000078003pfe:ViivHealthcareLimitedMember2021-07-052021-10-030000078003pfe:ViivHealthcareLimitedMember2022-01-012022-10-020000078003pfe:ViivHealthcareLimitedMember2021-01-012021-10-030000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-01-012022-07-030000078003srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:CorporateNonSegmentMember2022-01-012022-07-030000078003srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:CorporateNonSegmentMember2021-07-052021-10-030000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-07-052021-10-030000078003srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:CorporateNonSegmentMember2021-01-012021-10-030000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2021-01-012021-10-030000078003pfe:ReViralAssetAcquisitionMember2022-07-042022-10-020000078003pfe:ReViralAssetAcquisitionMember2022-01-012022-10-020000078003pfe:PaxlovidMemberus-gaap:CorporateNonSegmentMember2022-07-042022-10-020000078003pfe:PaxlovidMemberus-gaap:CorporateNonSegmentMember2022-01-012022-10-020000078003us-gaap:CollaborativeArrangementMemberpfe:ArvinasIncMember2021-01-012021-10-030000078003us-gaap:CollaborativeArrangementMemberpfe:ArvinasIncMember2021-07-052021-10-030000078003country:US2022-07-042022-10-020000078003country:US2021-07-052021-10-030000078003country:US2022-01-012022-10-020000078003country:US2021-01-012021-10-030000078003pfe:DevelopedEuropeMember2022-07-042022-10-020000078003pfe:DevelopedEuropeMember2021-07-052021-10-030000078003pfe:DevelopedEuropeMember2022-01-012022-10-020000078003pfe:DevelopedEuropeMember2021-01-012021-10-030000078003pfe:DevelopedRestOfWorldMember2022-07-042022-10-020000078003pfe:DevelopedRestOfWorldMember2021-07-052021-10-030000078003pfe:DevelopedRestOfWorldMember2022-01-012022-10-020000078003pfe:DevelopedRestOfWorldMember2021-01-012021-10-030000078003pfe:EmergingMarketsMember2022-07-042022-10-020000078003pfe:EmergingMarketsMember2021-07-052021-10-030000078003pfe:EmergingMarketsMember2022-01-012022-10-020000078003pfe:EmergingMarketsMember2021-01-012021-10-030000078003us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberpfe:GovernmentAndGovernmentSponsoredMemberpfe:ComirnatyAndPaxlovidMember2022-07-042022-10-020000078003us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberpfe:GovernmentAndGovernmentSponsoredMemberpfe:ComirnatyAndPaxlovidMember2022-01-012022-10-020000078003us-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMemberpfe:GovernmentAndGovernmentSponsoredMemberpfe:ComirnatyAndPaxlovidMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:PrimaryCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:PrimaryCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:PrimaryCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:PrimaryCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:ComirnatyMemberpfe:PrimaryCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:ComirnatyMemberpfe:PrimaryCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:ComirnatyMemberpfe:PrimaryCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:ComirnatyMemberpfe:PrimaryCareMember2021-01-012021-10-030000078003pfe:PaxlovidMemberpfe:BiopharmaSegmentMemberpfe:PrimaryCareMember2022-07-042022-10-020000078003pfe:PaxlovidMemberpfe:BiopharmaSegmentMemberpfe:PrimaryCareMember2021-07-052021-10-030000078003pfe:PaxlovidMemberpfe:BiopharmaSegmentMemberpfe:PrimaryCareMember2022-01-012022-10-020000078003pfe:PaxlovidMemberpfe:BiopharmaSegmentMemberpfe:PrimaryCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:EliquisMemberpfe:PrimaryCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:EliquisMemberpfe:PrimaryCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:EliquisMemberpfe:PrimaryCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:EliquisMemberpfe:PrimaryCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:PrevnarPrevenarFamilyMemberpfe:PrimaryCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:PrevnarPrevenarFamilyMemberpfe:PrimaryCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:PrevnarPrevenarFamilyMemberpfe:PrimaryCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:PrevnarPrevenarFamilyMemberpfe:PrimaryCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:PremarinFamilyMemberpfe:PrimaryCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:PremarinFamilyMemberpfe:PrimaryCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:PremarinFamilyMemberpfe:PrimaryCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:PremarinFamilyMemberpfe:PrimaryCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:NimenrixMemberpfe:PrimaryCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:NimenrixMemberpfe:PrimaryCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:NimenrixMemberpfe:PrimaryCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:NimenrixMemberpfe:PrimaryCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:BMP2Memberpfe:PrimaryCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:BMP2Memberpfe:PrimaryCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:BMP2Memberpfe:PrimaryCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:BMP2Memberpfe:PrimaryCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:FSMEIMMUNTicoVacMemberpfe:PrimaryCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:FSMEIMMUNTicoVacMemberpfe:PrimaryCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:FSMEIMMUNTicoVacMemberpfe:PrimaryCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:FSMEIMMUNTicoVacMemberpfe:PrimaryCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:ToviazMemberpfe:PrimaryCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:ToviazMemberpfe:PrimaryCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:ToviazMemberpfe:PrimaryCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:ToviazMemberpfe:PrimaryCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:PrimaryCareMemberpfe:TrumenbaMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:PrimaryCareMemberpfe:TrumenbaMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:PrimaryCareMemberpfe:TrumenbaMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:PrimaryCareMemberpfe:TrumenbaMember2021-01-012021-10-030000078003pfe:ChantixChampixMemberpfe:BiopharmaSegmentMemberpfe:PrimaryCareMember2022-07-042022-10-020000078003pfe:ChantixChampixMemberpfe:BiopharmaSegmentMemberpfe:PrimaryCareMember2021-07-052021-10-030000078003pfe:ChantixChampixMemberpfe:BiopharmaSegmentMemberpfe:PrimaryCareMember2022-01-012022-10-020000078003pfe:ChantixChampixMemberpfe:BiopharmaSegmentMemberpfe:PrimaryCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:OtherPrimaryCareProductsMemberpfe:PrimaryCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:OtherPrimaryCareProductsMemberpfe:PrimaryCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:OtherPrimaryCareProductsMemberpfe:PrimaryCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:OtherPrimaryCareProductsMemberpfe:PrimaryCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:VyndaqelMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:VyndaqelMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:VyndaqelMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:VyndaqelMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:XeljanzMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:XeljanzMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:XeljanzMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:XeljanzMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:EnbrelMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:EnbrelMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:EnbrelMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:EnbrelMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:SpecialtyCareMemberpfe:SulperazonMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:SpecialtyCareMemberpfe:SulperazonMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:SpecialtyCareMemberpfe:SulperazonMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:SpecialtyCareMemberpfe:SulperazonMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:InflectraMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:InflectraMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:InflectraMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:InflectraMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:IgPortfolioProductsMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:IgPortfolioProductsMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:IgPortfolioProductsMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:IgPortfolioProductsMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:BeneFIXMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:BeneFIXMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:BeneFIXMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:BeneFIXMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:ZaviceftaMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:ZaviceftaMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:ZaviceftaMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:ZaviceftaMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:SpecialtyCareMemberpfe:GenotropinMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:SpecialtyCareMemberpfe:GenotropinMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:SpecialtyCareMemberpfe:GenotropinMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:SpecialtyCareMemberpfe:GenotropinMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:ZithromaxZmaxMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:ZithromaxZmaxMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:ZithromaxZmaxMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:ZithromaxZmaxMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:MedrolMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:MedrolMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:MedrolMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:MedrolMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:FragminMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:FragminMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:FragminMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:FragminMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:SomavertMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:SomavertMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:SomavertMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:SomavertMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:ReFactoAfXynthaMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:ReFactoAfXynthaMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:ReFactoAfXynthaMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:ReFactoAfXynthaMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:VfendMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:VfendMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:VfendMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:VfendMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:OtherAntiinfectivesMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:OtherAntiinfectivesMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:OtherAntiinfectivesMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:OtherAntiinfectivesMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:BiopharmaSegmentMemberpfe:OtherSpecialtyCareMemberpfe:SpecialtyCareMember2022-07-042022-10-020000078003pfe:BiopharmaSegmentMemberpfe:OtherSpecialtyCareMemberpfe:SpecialtyCareMember2021-07-052021-10-030000078003pfe:BiopharmaSegmentMemberpfe:OtherSpecialtyCareMemberpfe:SpecialtyCareMember2022-01-012022-10-020000078003pfe:BiopharmaSegmentMemberpfe:OtherSpecialtyCareMemberpfe:SpecialtyCareMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:IbranceMemberpfe:BiopharmaSegmentMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:IbranceMemberpfe:BiopharmaSegmentMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:IbranceMemberpfe:BiopharmaSegmentMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:IbranceMemberpfe:BiopharmaSegmentMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:XtandiAllianceRevenuesMemberpfe:BiopharmaSegmentMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:XtandiAllianceRevenuesMemberpfe:BiopharmaSegmentMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:XtandiAllianceRevenuesMemberpfe:BiopharmaSegmentMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:XtandiAllianceRevenuesMemberpfe:BiopharmaSegmentMember2021-01-012021-10-030000078003pfe:InlytaMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2022-07-042022-10-020000078003pfe:InlytaMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2021-07-052021-10-030000078003pfe:InlytaMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2022-01-012022-10-020000078003pfe:InlytaMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:ZirabevMemberpfe:BiopharmaSegmentMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:ZirabevMemberpfe:BiopharmaSegmentMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:ZirabevMemberpfe:BiopharmaSegmentMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:ZirabevMemberpfe:BiopharmaSegmentMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BosulifMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BosulifMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BosulifMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BosulifMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:XalkoriMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:XalkoriMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:XalkoriMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:XalkoriMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:RuxienceMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:RuxienceMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:RuxienceMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:RuxienceMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:RetacritMemberpfe:BiopharmaSegmentMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:RetacritMemberpfe:BiopharmaSegmentMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:RetacritMemberpfe:BiopharmaSegmentMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:RetacritMemberpfe:BiopharmaSegmentMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:SutentMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:SutentMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:SutentMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:SutentMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:LorbrenaMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:LorbrenaMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:LorbrenaMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:LorbrenaMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BavencioAllianceRevenuesMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BavencioAllianceRevenuesMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BavencioAllianceRevenuesMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BavencioAllianceRevenuesMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:AromasinMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:AromasinMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:AromasinMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:AromasinMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BesponsaMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BesponsaMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BesponsaMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BesponsaMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BraftoviMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BraftoviMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BraftoviMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BraftoviMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:TrazimeraMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:TrazimeraMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:TrazimeraMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:TrazimeraMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:MektoviMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:MektoviMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:MektoviMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:MektoviMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:OtherOncologyProductsMember2022-07-042022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:OtherOncologyProductsMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:OtherOncologyProductsMember2022-01-012022-10-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:OtherOncologyProductsMember2021-01-012021-10-030000078003pfe:PfizerCentreOneSegmentMember2022-07-042022-10-020000078003pfe:PfizerCentreOneSegmentMember2021-07-052021-10-030000078003pfe:PfizerCentreOneSegmentMember2022-01-012022-10-020000078003pfe:PfizerCentreOneSegmentMember2021-01-012021-10-030000078003pfe:TotalAllianceBiopharmaceuticalsMember2022-07-042022-10-020000078003pfe:TotalAllianceBiopharmaceuticalsMember2021-07-052021-10-030000078003pfe:TotalAllianceBiopharmaceuticalsMember2022-01-012022-10-020000078003pfe:TotalAllianceBiopharmaceuticalsMember2021-01-012021-10-030000078003pfe:PfizerCentreOneSegmentMemberpfe:BioNTechMember2022-07-042022-10-020000078003pfe:PfizerCentreOneSegmentMemberpfe:BioNTechMember2022-01-012022-10-020000078003pfe:PfizerCentreOneSegmentMemberpfe:BioNTechMember2021-07-052021-10-030000078003pfe:PfizerCentreOneSegmentMemberpfe:BioNTechMember2021-01-012021-10-0300000780032022-10-032022-10-0200000780032023-01-012022-10-0200000780032024-01-012022-10-020000078003pfe:GovernmentAndGovernmentSponsoredMemberpfe:ComirnatyAndPaxlovidMember2022-10-020000078003pfe:ComirnatyMemberpfe:GovernmentAndGovernmentSponsoredMember2021-12-310000078003pfe:PaxlovidMemberpfe:GovernmentAndGovernmentSponsoredMember2021-12-310000078003pfe:ComirnatyMemberpfe:GovernmentAndGovernmentSponsoredMember2022-07-042022-10-020000078003pfe:ComirnatyMemberpfe:GovernmentAndGovernmentSponsoredMember2022-01-012022-10-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 2, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______


COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware13-5315170
(State of Incorporation)(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York  10017
(Address of principal executive offices)  (zip code)
(212) 733-2323
(Registrant’s telephone number)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YesxNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YesxNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x              Accelerated filer                 Non-accelerated filer            Smaller reporting company      Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YesNo
x

At November 4, 2022, 5,613,314,537 shares of the issuer’s voting common stock were outstanding.



TABLE OF CONTENTS
Page
 
 
Item 2.
 
 
 
 
 
 
Item 3. 
Defaults Upon Senior SecuritiesN/A
Item 4. 
Mine Safety DisclosuresN/A
Item 5. 
Other InformationN/A
 
N/A = Not Applicable
2


DEFINED TERMS

Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer’s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 28, 2022 and August 29, 2021, and for U.S. subsidiaries is as of and for the three and nine months ended October 2, 2022 and October 3, 2021. References to “Notes” in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2021 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:
2021 Form 10-KAnnual Report on Form 10-K for the fiscal year ended December 31, 2021
ACIPAdvisory Committee on Immunization Practices
ALKanaplastic lymphoma kinase
Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
ArenaArena Pharmaceuticals, Inc.
AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ArvinasArvinas, Inc.
ATTR-CMtransthyretin amyloid cardiomyopathy
BiohavenBiohaven Pharmaceutical Holding Company Ltd.
BioNTechBioNTech SE
BiopharmaGlobal Biopharmaceuticals Business
BLABiologics License Application
BMSBristol-Myers Squibb Company
BODBoard of Directors
CDCU.S. Centers for Disease Control and Prevention
CGRPcalcitonin gene-related peptide
CMA
conditional marketing authorisation
Comirnaty*
Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), the Comirnaty Original/Omicron BA.1 Vaccine, and Comirnaty Original/Omicron BA.4/BA.5 Vaccine
Cond. J-NDAConditional Japan New Drug Application
Consumer Healthcare JVGSK Consumer Healthcare JV
COVID-19novel coronavirus disease of 2019
Developed Europe
Includes the following markets: Western Europe, Scandinavian countries and Finland
Developed MarketsIncludes the following markets: U.S., Developed Europe, Japan, Australia, Canada, South Korea and New Zealand
Developed Rest of World
Includes the following markets: Japan, Australia, Canada, South Korea and New Zealand
ECEuropean Commission
EMAEuropean Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Central Europe, Eastern Europe, the Middle East, Africa and Turkey
EPSearnings per share
EUEuropean Union
EUAemergency use authorization
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
FDAU.S. Food and Drug Administration
FFDCAU.S. Federal Food, Drug and Cosmetic Act
Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended October 2, 2022
GAAPGenerally Accepted Accounting Principles
GISTgastrointestinal stromal tumors
GPDGlobal Product Development organization
GSKGlaxoSmithKline plc
HaleonHaleon plc
HIPAAHealth Insurance Portability and Accountability Act of 1996
HospiraHospira, Inc.
IPR&Din-process research and development
IRAInflation Reduction Act of 2022
IRSU.S. Internal Revenue Service
JAKJanus kinase
JVjoint venture
KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LIBORLondon Interbank Offered Rate
LOEloss of exclusivity
3


mCRCmetastatic colorectal cancer
mCRPC
metastatic castration-resistant prostate cancer
mCSPC
metastatic castration-sensitive prostate cancer
MD&AManagement’s Discussion and Analysis of Financial Condition and Results of Operations
MeridianMeridian Medical Technologies, Inc.
mRNAmessenger ribonucleic acid
MSAManufacturing Supply Agreement
MylanMylan N.V.
MyovantMyovant Sciences Ltd.
NDANew Drug Application
nmCRPC
non-metastatic castration-resistant prostate cancer
NSCLCnon-small cell lung cancer
ODToral disintegrating tablet
OPKOOPKO Health, Inc.
OTCover-the-counter
Paxlovid*an oral COVID-19 treatment (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)
PC1Pfizer CentreOne
PGSPfizer Global Supply
PharmaciaPharmacia Corporation
PRACPharmacovigilance Risk Assessment Committee
PsApsoriatic arthritis
QTDQuarter-to-date or three months ended
RArheumatoid arthritis
RCCrenal cell carcinoma
R&Dresearch and development
ReViralReViral Ltd.
SECU.S. Securities and Exchange Commission
sNDAsupplemental new drug application
TSAstransition service arrangements
UCulcerative colitis
U.K.United Kingdom
U.S.United States
Upjohn BusinessPfizer’s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris
ViatrisViatris Inc.
ViiVViiV Healthcare Limited
WRDMWorldwide Research, Development and Medical
YTD
Year-to-date or nine months ended
*Paxlovid and emergency uses of the Pfizer-BioNTech COVID-19 Vaccine or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), have not been approved or licensed by the FDA. Paxlovid has not been approved, but has been authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death. Emergency uses of the vaccines have been authorized by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months and older for the Pfizer-BioNTech COVID-19 Vaccine and 5 years and older for the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the FFDCA unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.
This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.
The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.
4


PART I.  FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
 Three Months EndedNine Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)October 2,
2022
October 3,
2021
October 2,
2022
October 3,
2021
Revenues$22,638 $24,035 $76,040 $57,450 
Costs and expenses:
Cost of sales(a)
6,063 9,932 24,696 21,085 
Selling, informational and administrative expenses(a)
3,391 2,899 9,032 8,599 
Research and development expenses(a)
2,696 2,681 7,813 6,914 
Acquired in-process research and development expenses(b)
524 762 880 1,000 
Amortization of intangible assets822 968 2,478 2,743 
Restructuring charges and certain acquisition-related costs199 646 580 667 
Other (income)/deductions––net(59)(1,696)1,063 (4,043)
Income from continuing operations before provision/(benefit) for taxes on income9,001 7,843 29,498 20,484 
Provision/(benefit) for taxes on income356 (328)3,098 1,603 
Income from continuing operations8,645 8,171 26,400 18,881 
Discontinued operations––net of tax(21)(13)4 (248)
Net income before allocation to noncontrolling interests8,623 8,159 26,404 18,633 
Less: Net income attributable to noncontrolling interests15 12 27 47 
Net income attributable to Pfizer Inc. common shareholders$8,608 $8,146 $26,378 $18,586 
Earnings per common share––basic:
    
Income from continuing operations attributable to Pfizer Inc. common shareholders$1.54 $1.45 $4.70 $3.37 
Discontinued operations––net of tax   (0.04)
Net income attributable to Pfizer Inc. common shareholders$1.54 $1.45 $4.71 $3.32 
Earnings per common share––diluted:
    
Income from continuing operations attributable to Pfizer Inc. common shareholders$1.51 $1.43 $4.60 $3.31 
Discontinued operations––net of tax   (0.04)
Net income attributable to Pfizer Inc. common shareholders$1.51 $1.42 $4.60 $3.27 
Weighted-average shares––basic5,607 5,609 5,606 5,597 
Weighted-average shares––diluted5,718 5,725 5,729 5,688 
(a)Exclusive of amortization of intangible assets.
(b)See Note 1D.
See Accompanying Notes.
5


PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
 Three Months EndedNine Months Ended
(MILLIONS)October 2,
2022
October 3,
2021
October 2,
2022
October 3,
2021
Net income before allocation to noncontrolling interests$8,623 $8,159 $26,404 $18,633 
Foreign currency translation adjustments, net(918)(866)(2,549)(366)
Unrealized holding gains/(losses) on derivative financial instruments, net589 213 1,443 179 
Reclassification adjustments for (gains)/losses included in net income(a)
(615)48 (972)286 
 (26)261 471 464 
Unrealized holding gains/(losses) on available-for-sale securities, net(777)(266)(1,397)(128)
Reclassification adjustments for (gains)/losses included in net income(b)
606 9 1,094 (172)
 (171)(257)(303)(300)
Reclassification adjustments related to amortization of prior service costs and other, net(31)(39)(99)(119)
Reclassification adjustments related to curtailments of prior service costs and other, net2 (58)(8)(62)
 (29)(97)(107)(181)
Other comprehensive income/(loss), before tax(1,144)(959)(2,488)(382)
Tax provision/(benefit) on other comprehensive income/(loss)(33)(65)(149)(44)
Other comprehensive income/(loss) before allocation to noncontrolling interests$(1,111)$(894)$(2,339)$(338)
Comprehensive income/(loss) before allocation to noncontrolling interests$7,512 $7,265 $24,065 $18,296 
Less: Comprehensive income/(loss) attributable to noncontrolling interests10 9 16 48 
Comprehensive income/(loss) attributable to Pfizer Inc.$7,503 $7,256 $24,049 $18,248 
(a)Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
(b)Reclassified into Other (income)/deductions—net.
See Accompanying Notes.
6


PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS)October 2,
2022
December 31, 2021
(Unaudited)
Assets
Cash and cash equivalents$1,298 $1,944 
Short-term investments34,825 29,125 
Trade accounts receivable, less allowance for doubtful accounts: 2022—$474; 2021—$492
16,076 11,479 
Inventories9,513 9,059 
Current tax assets2,544 4,266 
Other current assets6,149 3,820 
Total current assets70,403 59,693 
Equity-method investments9,826 16,472 
Long-term investments4,062 5,054 
Property, plant and equipment, less accumulated depreciation: 2022—$14,931; 2021—$15,074
15,441 14,882 
Identifiable intangible assets28,151 25,146 
Goodwill49,441 49,208 
Noncurrent deferred tax assets and other noncurrent tax assets7,136 3,341 
Other noncurrent assets10,890 7,679 
Total assets$195,350 $181,476 
Liabilities and Equity  
Short-term borrowings, including current portion of long-term debt: 2022—$2,566; 2021—$1,636
$4,040 $2,241 
Trade accounts payable6,267 5,578 
Dividends payable2,245 2,249 
Income taxes payable3,071 1,266 
Accrued compensation and related items2,852 3,332 
Deferred revenues6,191 3,067 
Other current liabilities19,647 24,939 
Total current liabilities44,314 42,671 
Long-term debt32,629 36,195 
Pension benefit obligations2,738 3,489 
Postretirement benefit obligations222 235 
Noncurrent deferred tax liabilities616 349 
Other taxes payable9,701 11,331 
Other noncurrent liabilities12,239 9,743 
Total liabilities102,459 104,013 
Commitments and Contingencies
Common stock476 473 
Additional paid-in capital91,359 90,591 
Treasury stock(113,945)(111,361)
Retained earnings122,967 103,394 
Accumulated other comprehensive loss(8,225)(5,897)
Total Pfizer Inc. shareholders’ equity92,631 77,201 
Equity attributable to noncontrolling interests259 262 
Total equity92,891 77,462 
Total liabilities and equity$195,350 $181,476 
See Accompanying Notes.
7


PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER COMMON SHARE DATA)SharesPar ValueAdd’l
Paid-In Capital
SharesCostRetained EarningsAccum. Other Comp.
Loss
Share-
holders’ Equity
Non-controlling interestsTotal Equity
Balance, July 3, 2022
9,496 $476 $91,183 (3,903)$(113,939)$116,608 $(7,119)$87,208 $261 $87,469 
Net income8,608 8,608 15 8,623 
Other comprehensive income/(loss), net of tax
(1,106)(1,106)(5)(